OTCMKTS:USRM - US Stem Cell Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding US Stem Cell Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.0055 0.00 (0.00 %) (As of 03/29/2020 04:00 PM ET) Add Compare Today's Range$0.00Now: $0.01▼$0.0150-Day Range$0.00MA: $0.01▼$0.0152-Week Range$0.00Now: $0.01▼$0.03Volume2.27 million shsAverage Volume791,477 shsMarket Capitalization$2.34 millionP/E RatioN/ADividend YieldN/ABeta5.29 ProfileAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.Read More Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:USRM Previous SymbolNASDAQ:BHRT CUSIPN/A CIKN/A Webhttp://www.us-stemcell.com/ Phone954-835-1500Debt Debt-to-Equity RatioN/A Current Ratio0.02 Quick Ratio0.02Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.70 million Price / Sales0.35 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-0.28Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-2,160,000.00 Net Margins-81.39% Return on EquityN/A Return on Assets-313.05%Miscellaneous Employees10 Outstanding Shares424,940,000Market Cap$2.34 million Next Earnings Date4/1/2020 (Estimated) OptionableNot Optionable Receive USRM News and Ratings via Email Sign-up to receive the latest news and ratings for USRM and its competitors with MarketBeat's FREE daily newsletter. OTC:USRM Rates by TradingView US Stem Cell (OTCMKTS:USRM) Frequently Asked Questions How has US Stem Cell's stock been impacted by COVID-19 (Coronavirus)? US Stem Cell's stock was trading at $0.0061 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, USRM shares have decreased by 9.8% and is now trading at $0.0055. View which stocks have been mosted impacted by Coronavirus. When is US Stem Cell's next earnings date? US Stem Cell is scheduled to release its next quarterly earnings announcement on Wednesday, April 1st 2020. View our earnings forecast for US Stem Cell. How were US Stem Cell's earnings last quarter? US Stem Cell Inc (OTCMKTS:USRM) announced its quarterly earnings results on Wednesday, August, 7th. The company reported $0.00 earnings per share (EPS) for the quarter. The company had revenue of $1.30 million for the quarter. View US Stem Cell's earnings history. Has US Stem Cell been receiving favorable news coverage? News coverage about USRM stock has been trending extremely negative this week, InfoTrie reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. US Stem Cell earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future. View the latest news aboutUS Stem Cell. Who are some of US Stem Cell's key competitors? Some companies that are related to US Stem Cell include Tenax Therapeutics (TENX), Vitality Biopharma (VBIO), Geovax Labs (GOVX), Protalex (PRTX), ALGAE TEC LTD/S (ALGXY) and Redpoint Bio (RPBC). What other stocks do shareholders of US Stem Cell own? Based on aggregate information from My MarketBeat watchlists, some companies that other US Stem Cell investors own include Cleveland BioLabs (CBLI), Digi International (DGII), Micron Technology (MU), SeaChange International (SEAC), SMTC (SMTX), Actinium Pharmaceuticals (ATNM), Alexion Pharmaceuticals (ALXN), Axsome Therapeutics (AXSM), Chimerix (CMRX) and Constellation Pharmaceuticals (CNST). Who are US Stem Cell's key executives? US Stem Cell's management team includes the following people: Mr. Michael Tomas, CEO, Pres, CFO & Director (Age 53)Dr. Kristin C. Comella Ph.D., Chief Science Officer & Director (Age 42)Dr. Colleen Robb, Sr. Compliance OfficerMr. Phil Posa, Sr. VP of U.S. & International SalesMs. Evelyn Flores, Corp. Controller What is US Stem Cell's stock symbol? US Stem Cell trades on the OTCMKTS under the ticker symbol "USRM." How do I buy shares of US Stem Cell? Shares of USRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is US Stem Cell's stock price today? One share of USRM stock can currently be purchased for approximately $0.01. How big of a company is US Stem Cell? US Stem Cell has a market capitalization of $2.34 million and generates $6.70 million in revenue each year. US Stem Cell employs 10 workers across the globe. View additional information about US Stem Cell. What is US Stem Cell's official website? The official website for US Stem Cell is http://www.us-stemcell.com/. How can I contact US Stem Cell? US Stem Cell's mailing address is 1560 SAWGRASS CORPORATE PKWY 4TH FLOOR, SUNRISE FL, 33325. The company can be reached via phone at 954-835-1500 or via email at [email protected] MarketBeat Community Rating for US Stem Cell (OTCMKTS USRM)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 131 (Vote Outperform)Underperform Votes: 104 (Vote Underperform)Total Votes: 235MarketBeat's community ratings are surveys of what our community members think about US Stem Cell and other stocks. Vote "Outperform" if you believe USRM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe USRM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/29/2020 by MarketBeat.com StaffFeatured Article: How to interpret a stock’s beta number
